RZLT Rezolute, Inc.
USHealthcareAs of 2026-07-10 16:00
Why RZLT matters now
Rezolute, Inc. (RZLT) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.75 with -7.41% on the session and $457.4M in market capitalization; recent performance reads 1-month +61.94% and YTD +112.71%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-16.2M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.2%.
The latest indexable market news headline is "Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Evans Daron filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.47
P/S
0.00
EV/EBITDA
-5.81
DCF Value
$1.15
FCF Yield
-15.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-58.8%
ROA
-64.9%
ROIC
-73.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-16.2M | $-0.16 |
| Q2 2026 | $0.00 | $-22.8M | $-0.22 |
| Q1 2026 | $0.00 | $-18.1M | $-0.18 |
| Q4 2025 | $0.00 | $-24.4M | $-0.26 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.67
Target (Median)
$6.00
Target Range
$6.00 - $14.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.65
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.